What we claim is:

1. A diagnosis method for determining if an individual having clinical characteristics of the primary antiphospholipid syndrome or diseases associated to the secondary antiphospholipid syndrome, and who does not present yet anti-cardiolipine antibodies, lupus anticoagulant, anti-DNA or antinuclear antibodies; does have a disease associated to the presence of antiphospholipid antibodies; comprising the steps of detecting, in a direct or indirect fashion, the presence or absence of lipidic particles in a serum sample from said individual, and observing whether lipidic particles are detected or not; where the presence of said lipidic particles indicates the development of a disease associated to the presence of antiphospholipid antibodies in said individual.

2. A method in accordance with claim 1, wherein the step of detecting lipidic particles is carried out in an indirect fashion by reacting an antigen containing lipidic particles with ~~a sample from the individual~~ the serum sample in order to determine whether said sample contains anti-lipidic particles antibodies; and where the detection protocol is selected from the group consisting of cytofluorometry, immunofluorescence and ELISA methods.

3. ~~A~~ method in accordance with claim 1, wherein the sample from said individual is selected between serum and ~~plasma~~ of said individual, and the antigen containing lipidic particles is selected between neoplastic cells and ~~liposomes~~.

4. A method in accordance with claim 1, further including the step of reacting the antigen with ~~at least~~ at least one of an anti-lipidic particles polyclonal ~~or~~ and monoclonal antibody in order to confirm whether anti-lipidic particles antibodies are present or not in said ~~individual's~~ serum sample.

5. A method in accordance with claim 1, wherein the step of detecting lipidic particles is carried out in a direct fashion by reacting cells from the individual with ~~at least~~ at least one of an anti-lipid particles polyclonal ~~or~~ and monoclonal antibody, and wherein the detection protocol is selected from the group consisting of immunofluorescence, cytofluorometry and ELISA methods.

6. A diagnosis kit for detecting anti-lipidic particles antibodies in a sample from an individual suffering from a disease associated to antiphospholipid antibodies, comprising:

a) an indicator reagent including firstly ~~at least~~ liposomes having lipidic particles, and secondly ~~at least~~ an anti-lipidic particles monoclonal antibody;

b) ~~at least~~ a blocking solution to prevent possible false positive results from occurring;

c) ~~at least~~ a buffer solution as a medium to allow the reaction between the ~~individual's~~ sample and the indicator reagent to proceed; and

d) enzymatic means to make evident said reaction.

7. A diagnosis kit for detecting anti-lipidic particles antibodies in a sample from an individual suffering from a disease associated to antiphospholipid antibodies, in accordance with claim 6, ~~wherein enzymatic~~ wherein the enzymatic means include antibodies conjugated to an enzyme selected from the group consisting of peroxidase and alkaline phosphatase.

8. A diagnosis kit in accordance with claim 7, wherein the sample is selected ~~between~~ from serum and plasma from said individual.

9. A diagnosis kit in accordance with claim 8, further including ~~at least a sample~~ a reference sample of a reference serum from a healthy individual as a negative control of the reaction with liposomal antigens containing lipidic particles.

10. A diagnosis kit in accordance with claim ~~9,~~ further including means to carry out the reaction of the type of microtiter plates.

11. A diagnosis kit for detecting anti-lipidic particles antibodies in a sample from an individual suffering from a disease associated to antiphospholipid antibodies, comprising:

a) an indicator reagent including liposomes having lipidic particles;

b) ~~at least~~ a buffer solution as a medium to allow the reaction between the ~~individual's~~ sample and the indicator reagent to proceed; and

c) fluorescent means to make evident said reaction.

12. A diagnosis kit for detecting anti-lipidic particles antibodies in a sample from an individual suffering from a disease associated to antiphospholipid antibodies, in accordance with claim 11 wherein the fluorescent means comprise antibodies conjugated to a fluorochrome selected from the group consisting of fluorescein isothiocyanate, phycoerythrin, Cy3 and Percp.

13. A diagnosis kit in accordance with claim 12, wherein the sample is selected ~~between~~ from serum and plasma from said individual.

14. A diagnosis kit in accordance with claim 13, further including ~~at least~~ an anti-lipidic particles monoclonal antibody as a positive control of the reaction with liposomal antigens; and ~~at least a sample~~ a reference sample of a reference serum from a healthy individual as a negative control of the reaction with liposomal antigens containing lipidic particles.

15. A diagnosis kit in accordance with claim 14, further including means to carry out the reaction of the type of centrifugation tubes.

16. A diagnosis kit for the direct detection of lipidic particles in a sample from an individual suffering from a disease associated to antiphospholipid antibodies, comprising:

a) an indicator reagent consisting of ~~at least~~ an anti-lipidic particles monoclonal antibody;

b) ~~at least~~ a buffer solution as a medium to allow the reaction between the ~~individual's~~ sample and the indicator reagent to proceed; and

c) ~~fluorescent~~ means to make evident said reaction.

17. A diagnosis kit for the direct detection of lipidic particles in a sample from an individual suffering from a disease associated to antiphospholipid antibodies, in accordance with claim 16 wherein the means to make evident said reaction are enzymatic means.

18. A diagnosis kit in accordance with ~~claims 16 or 17~~ claim 16, wherein the fluorescent means and the enzymatic means comprise antibodies conjugated to a fluorochrome and an enzyme, respectively.

19. A diagnosis kit for the direct detection of lipidic particles in a sample from an individual suffering from a disease associated to antiphospholipid antibodies, in accordance with claim 18, wherein the fluorochrome is selected from the group consisting of fluorescein isothiocyanate, phycoerythrin, Cy3 and Percp; and the enzyme is selected from the group consisting of peroxidase and alkaline phosphatase.

20. A diagnosis kit in accordance with claim 19, wherein the sample is selected from organ cells of said individual.

21. A diagnosis kit in accordance with claim 20, further including means to carry out the reaction of the type of cellular culture microtiter plates.

22. A therapeutic method for the treatment of an individual having clinical characteristics of the primary antiphospholipid syndrome or diseases associated with the secondary antiphospholipid syndrome, and who does not present yet anti-cardiolipine antibodies, lupus anticoagulant, anti-DNA or antinuclear antibodies, and scoring an anti-lipidic particles antibodies titer of Arbitrary Units ≤ 50 comprising administering to said individual a therapeutically effective quantity of a cellular membrane stabilizer drug.

23. A therapeutic method in accordance with claim 22, wherein the stabilizer drug is selected from the group consisting of polyamines of the type of the putrescine, spermidine and spermin, and from the group consisting of antimalaric drugs of the type of the chloroquine, hydroxichloroquine, amadoquine, quinacrine and primaquine

24. A therapeutic method for the treatment of an individual having clinical characteristics of the primary antiphospholipid syndrome or diseases associated with the secondary antiphospholipid syndrome, and who does not present yet anti-cardiolipine antibodies, lupus anticoagulant, anti-DNA or antinuclear antibodies, and scoring an anti-lipidic particles antibodies titer of Arbitrary Units > 50 comprising administering to said individual a therapeutically effective quantity of an anti-lipidic particles antibody inhibitor drug; followed by the administration of a therapeutically effective quantity of a cellular membrane stabilizer drug.

25. A therapeutic method in accordance with claim 24, wherein the anti-lipidic particles antibody inhibitor drug is selected from the group consisting of phosphorylated haptens of the type of the phosphorylcholine and glycerolphosphorylcholine, and the cellular membrane stabilizer drug is selected from the group consisting of polyamines of the type of the putrescine, spermidine and spermine, and from the group consisting of antimalaric drugs of the type of the chloroquine, hydroxichloroquine, amadoquine, quinacrine and primaquine.

26. A method for determining different cellular physiologic states in cells, ~~characterized in that it includes the detection of~~ comprising detecting lipidic particles in membranes of said cells.

27. A detection kit for determining different cellular physiologic states in a sample of cells, comprising:

a) an indicator reagent consisting of ~~at least~~ an anti-lipidic particles monoclonal antibody;

b) ~~at least~~ a buffer solution as a medium to allow the reaction between the cells in diverse physiologic states and the indicator reagent to proceed; and

c) ~~fluorescent or~~ enzymatic means to make evident said reaction.

28. A detection kit in accordance with claim 27, wherein the fluorescent means and the enzymatic means comprise antibodies conjugated to a fluorochrome and an enzyme, respectively.

29. A detection kit in accordance with ~~claim 28,~~ wherein the fluorochrome is selected from the group consisting of fluorescein isothiocyanate, phycoerythrin, Cy3

and Percp; and the enzyme is selected from the group consisting of peroxidase and alkaline phosphatase.

30. A detection kit for determining different cellular physiologic states in a sample of cells in accordance with claim 29, wherein the cells are selected from the group consisting of isolated cells and cells in microsections of organs from human and non-human subjects.

31. A detection kit in accordance with claim 30, further including means to carry out the detection of the type of cellular culture microtiter plates.